Largest, independent, prospective study demonstrates utility of decisiondx®-melanoma for prediction of outcomes in patients with cutaneous melanoma referred for sentinel node biopsy

Friendswood, texas--(business wire)---- $cstl #castlebiosciences--castle biosciences, inc. (nasdaq: cstl), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced data from an independent, prospective study published in the american journal of surgery demonstrating decisiondx®-melanoma's utility for prediction of outcomes in patients with cutaneous melanoma. decisiondx-melanoma is castle's gene expression profile test that uses an individual patien
CSTL Ratings Summary
CSTL Quant Ranking